touchRESPIRATORY touchRESPIRATORY
Play ArrowPlay Video

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which of the following topics do you feel will be most relevant to your practice?

Submit your answer to see the results

EGFR-mutations and targeted therapies
   
Emerging treatments and clinical trials for wildtype NSCLC
   
Patient support strategies and education
   
Biomarker testing for risk stratification
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

What emerging trends in biomarker testing are you most excited about?

Submit your answer to see the results

Development of novel biomarkers
   
Integration of liquid biopsies
   
Comprehensive genomic profiling
   
AI-enhanced analysis
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

What do you consider the biggest challenge for patients when navigating the NSCLC care pathway?

Submit your answer to see the results

Understanding treatment options
   
Managing side effects
   
Providing patient education and support
   
Communicating with healthcare providers
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

What are you most interested in learning about from ongoing clinical trials?

Submit your answer to see the results

Management of hard-to-treat patients
   
Options for second-line treatments (e.g. ADCs)
   
Outcomes in non-squamous vs squamous patients
   
Improved outcomes in the first-line setting
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which of the following trials is most likely to be most practice changing?

Submit your answer to see the results

HARMONi-2
   
TROPION-Lung01
   
EVOKE-02
   
Other
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which is the most important for drug development in late-stage EGFR-wildtype NSCLC?

Submit your answer to see the results

Novel combinations, including dual immunotherapy options
   
Tumour infiltrating lymphocytes (TILs)
   
Cancer vaccines
   
Antibody–drug conjugates
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

What are you most interested in learning about from ongoing clinical trials?

Submit your answer to see the results

Outcomes in patients with brain metastases
   
Outcomes in high-risk patients
   
Role of biomarkers in personalizing treatment
   
Overall survival rates for combination approaches
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which of the following treatments is most likely to change your clinical practice?

Submit your answer to see the results

Osimertinib + chemotherapy
   
Amivantamab + lazertnib
   
Amivantamab + chemotherapy
   
Other
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which is the most important area for research in late-stage EGFR-mutant NSCLC?

Submit your answer to see the results

Management of CNS metastases/leptomeningeal disease
   
Biomarkers to monitor/predict treatment response
   
Identifying patients for risk-adaptive treatment strategies
   
Understanding specific resistance mutations
   
Play ArrowPlay Video

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which of the following topics do you feel will be most relevant to your practice?

Submit your answer to see the results

EGFR-mutations and targeted therapies
   
Emerging treatments and clinical trials for wildtype NSCLC
   
Patient support strategies and education
   
Biomarker testing for risk stratification
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

What emerging trends in biomarker testing are you most excited about?

Submit your answer to see the results

Development of novel biomarkers
   
Integration of liquid biopsies
   
Comprehensive genomic profiling
   
AI-enhanced analysis
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

What do you consider the biggest challenge for patients when navigating the NSCLC care pathway?

Submit your answer to see the results

Understanding treatment options
   
Managing side effects
   
Providing patient education and support
   
Communicating with healthcare providers
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

What are you most interested in learning about from ongoing clinical trials?

Submit your answer to see the results

Management of hard-to-treat patients
   
Options for second-line treatments (e.g. ADCs)
   
Outcomes in non-squamous vs squamous patients
   
Improved outcomes in the first-line setting
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which of the following trials is most likely to be most practice changing?

Submit your answer to see the results

HARMONi-2
   
TROPION-Lung01
   
EVOKE-02
   
Other
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which is the most important for drug development in late-stage EGFR-wildtype NSCLC?

Submit your answer to see the results

Novel combinations, including dual immunotherapy options
   
Tumour infiltrating lymphocytes (TILs)
   
Cancer vaccines
   
Antibody–drug conjugates
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

What are you most interested in learning about from ongoing clinical trials?

Submit your answer to see the results

Outcomes in patients with brain metastases
   
Outcomes in high-risk patients
   
Role of biomarkers in personalizing treatment
   
Overall survival rates for combination approaches
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which of the following treatments is most likely to change your clinical practice?

Submit your answer to see the results

Osimertinib + chemotherapy
   
Amivantamab + lazertnib
   
Amivantamab + chemotherapy
   
Other
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which is the most important area for research in late-stage EGFR-mutant NSCLC?

Submit your answer to see the results

Management of CNS metastases/leptomeningeal disease
   
Biomarkers to monitor/predict treatment response
   
Identifying patients for risk-adaptive treatment strategies
   
Understanding specific resistance mutations
   
Play ArrowPlay Video

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which of the following topics do you feel will be most relevant to your practice?

Submit your answer to see the results

EGFR-mutations and targeted therapies
   
Emerging treatments and clinical trials for wildtype NSCLC
   
Patient support strategies and education
   
Biomarker testing for risk stratification
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

What emerging trends in biomarker testing are you most excited about?

Submit your answer to see the results

Development of novel biomarkers
   
Integration of liquid biopsies
   
Comprehensive genomic profiling
   
AI-enhanced analysis
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

What do you consider the biggest challenge for patients when navigating the NSCLC care pathway?

Submit your answer to see the results

Understanding treatment options
   
Managing side effects
   
Providing patient education and support
   
Communicating with healthcare providers
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

What are you most interested in learning about from ongoing clinical trials?

Submit your answer to see the results

Management of hard-to-treat patients
   
Options for second-line treatments (e.g. ADCs)
   
Outcomes in non-squamous vs squamous patients
   
Improved outcomes in the first-line setting
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which of the following trials is most likely to be most practice changing?

Submit your answer to see the results

HARMONi-2
   
TROPION-Lung01
   
EVOKE-02
   
Other
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which is the most important for drug development in late-stage EGFR-wildtype NSCLC?

Submit your answer to see the results

Novel combinations, including dual immunotherapy options
   
Tumour infiltrating lymphocytes (TILs)
   
Cancer vaccines
   
Antibody–drug conjugates
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

What are you most interested in learning about from ongoing clinical trials?

Submit your answer to see the results

Outcomes in patients with brain metastases
   
Outcomes in high-risk patients
   
Role of biomarkers in personalizing treatment
   
Overall survival rates for combination approaches
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which of the following treatments is most likely to change your clinical practice?

Submit your answer to see the results

Osimertinib + chemotherapy
   
Amivantamab + lazertnib
   
Amivantamab + chemotherapy
   
Other
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which is the most important area for research in late-stage EGFR-mutant NSCLC?

Submit your answer to see the results

Management of CNS metastases/leptomeningeal disease
   
Biomarkers to monitor/predict treatment response
   
Identifying patients for risk-adaptive treatment strategies
   
Understanding specific resistance mutations
   
Play ArrowPlay Video

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which of the following topics do you feel will be most relevant to your practice?

Submit your answer to see the results

EGFR-mutations and targeted therapies
   
Emerging treatments and clinical trials for wildtype NSCLC
   
Patient support strategies and education
   
Biomarker testing for risk stratification
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

What emerging trends in biomarker testing are you most excited about?

Submit your answer to see the results

Development of novel biomarkers
   
Integration of liquid biopsies
   
Comprehensive genomic profiling
   
AI-enhanced analysis
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

What do you consider the biggest challenge for patients when navigating the NSCLC care pathway?

Submit your answer to see the results

Understanding treatment options
   
Managing side effects
   
Providing patient education and support
   
Communicating with healthcare providers
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

What are you most interested in learning about from ongoing clinical trials?

Submit your answer to see the results

Management of hard-to-treat patients
   
Options for second-line treatments (e.g. ADCs)
   
Outcomes in non-squamous vs squamous patients
   
Improved outcomes in the first-line setting
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which of the following trials is most likely to be most practice changing?

Submit your answer to see the results

HARMONi-2
   
TROPION-Lung01
   
EVOKE-02
   
Other
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which is the most important for drug development in late-stage EGFR-wildtype NSCLC?

Submit your answer to see the results

Novel combinations, including dual immunotherapy options
   
Tumour infiltrating lymphocytes (TILs)
   
Cancer vaccines
   
Antibody–drug conjugates
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

What are you most interested in learning about from ongoing clinical trials?

Submit your answer to see the results

Outcomes in patients with brain metastases
   
Outcomes in high-risk patients
   
Role of biomarkers in personalizing treatment
   
Overall survival rates for combination approaches
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which of the following treatments is most likely to change your clinical practice?

Submit your answer to see the results

Osimertinib + chemotherapy
   
Amivantamab + lazertnib
   
Amivantamab + chemotherapy
   
Other
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which is the most important area for research in late-stage EGFR-mutant NSCLC?

Submit your answer to see the results

Management of CNS metastases/leptomeningeal disease
   
Biomarkers to monitor/predict treatment response
   
Identifying patients for risk-adaptive treatment strategies
   
Understanding specific resistance mutations
   
Play ArrowPlay Video

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which of the following topics do you feel will be most relevant to your practice?

Submit your answer to see the results

EGFR-mutations and targeted therapies
   
Emerging treatments and clinical trials for wildtype NSCLC
   
Patient support strategies and education
   
Biomarker testing for risk stratification
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

What emerging trends in biomarker testing are you most excited about?

Submit your answer to see the results

Development of novel biomarkers
   
Integration of liquid biopsies
   
Comprehensive genomic profiling
   
AI-enhanced analysis
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

What do you consider the biggest challenge for patients when navigating the NSCLC care pathway?

Submit your answer to see the results

Understanding treatment options
   
Managing side effects
   
Providing patient education and support
   
Communicating with healthcare providers
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

What are you most interested in learning about from ongoing clinical trials?

Submit your answer to see the results

Management of hard-to-treat patients
   
Options for second-line treatments (e.g. ADCs)
   
Outcomes in non-squamous vs squamous patients
   
Improved outcomes in the first-line setting
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which of the following trials is most likely to be most practice changing?

Submit your answer to see the results

HARMONi-2
   
TROPION-Lung01
   
EVOKE-02
   
Other
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which is the most important for drug development in late-stage EGFR-wildtype NSCLC?

Submit your answer to see the results

Novel combinations, including dual immunotherapy options
   
Tumour infiltrating lymphocytes (TILs)
   
Cancer vaccines
   
Antibody–drug conjugates
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

What are you most interested in learning about from ongoing clinical trials?

Submit your answer to see the results

Outcomes in patients with brain metastases
   
Outcomes in high-risk patients
   
Role of biomarkers in personalizing treatment
   
Overall survival rates for combination approaches
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which of the following treatments is most likely to change your clinical practice?

Submit your answer to see the results

Osimertinib + chemotherapy
   
Amivantamab + lazertnib
   
Amivantamab + chemotherapy
   
Other
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which is the most important area for research in late-stage EGFR-mutant NSCLC?

Submit your answer to see the results

Management of CNS metastases/leptomeningeal disease
   
Biomarkers to monitor/predict treatment response
   
Identifying patients for risk-adaptive treatment strategies
   
Understanding specific resistance mutations
   
Play ArrowPlay Video

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which of the following topics do you feel will be most relevant to your practice?

Submit your answer to see the results

EGFR-mutations and targeted therapies
   
Emerging treatments and clinical trials for wildtype NSCLC
   
Patient support strategies and education
   
Biomarker testing for risk stratification
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

What emerging trends in biomarker testing are you most excited about?

Submit your answer to see the results

Development of novel biomarkers
   
Integration of liquid biopsies
   
Comprehensive genomic profiling
   
AI-enhanced analysis
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

What do you consider the biggest challenge for patients when navigating the NSCLC care pathway?

Submit your answer to see the results

Understanding treatment options
   
Managing side effects
   
Providing patient education and support
   
Communicating with healthcare providers
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

What are you most interested in learning about from ongoing clinical trials?

Submit your answer to see the results

Management of hard-to-treat patients
   
Options for second-line treatments (e.g. ADCs)
   
Outcomes in non-squamous vs squamous patients
   
Improved outcomes in the first-line setting
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which of the following trials is most likely to be most practice changing?

Submit your answer to see the results

HARMONi-2
   
TROPION-Lung01
   
EVOKE-02
   
Other
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which is the most important for drug development in late-stage EGFR-wildtype NSCLC?

Submit your answer to see the results

Novel combinations, including dual immunotherapy options
   
Tumour infiltrating lymphocytes (TILs)
   
Cancer vaccines
   
Antibody–drug conjugates
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

What are you most interested in learning about from ongoing clinical trials?

Submit your answer to see the results

Outcomes in patients with brain metastases
   
Outcomes in high-risk patients
   
Role of biomarkers in personalizing treatment
   
Overall survival rates for combination approaches
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which of the following treatments is most likely to change your clinical practice?

Submit your answer to see the results

Osimertinib + chemotherapy
   
Amivantamab + lazertnib
   
Amivantamab + chemotherapy
   
Other
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which is the most important area for research in late-stage EGFR-mutant NSCLC?

Submit your answer to see the results

Management of CNS metastases/leptomeningeal disease
   
Biomarkers to monitor/predict treatment response
   
Identifying patients for risk-adaptive treatment strategies
   
Understanding specific resistance mutations
   
Play ArrowPlay Video

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which of the following topics do you feel will be most relevant to your practice?

Submit your answer to see the results

EGFR-mutations and targeted therapies
   
Emerging treatments and clinical trials for wildtype NSCLC
   
Patient support strategies and education
   
Biomarker testing for risk stratification
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

What emerging trends in biomarker testing are you most excited about?

Submit your answer to see the results

Development of novel biomarkers
   
Integration of liquid biopsies
   
Comprehensive genomic profiling
   
AI-enhanced analysis
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

What do you consider the biggest challenge for patients when navigating the NSCLC care pathway?

Submit your answer to see the results

Understanding treatment options
   
Managing side effects
   
Providing patient education and support
   
Communicating with healthcare providers
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

What are you most interested in learning about from ongoing clinical trials?

Submit your answer to see the results

Management of hard-to-treat patients
   
Options for second-line treatments (e.g. ADCs)
   
Outcomes in non-squamous vs squamous patients
   
Improved outcomes in the first-line setting
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which of the following trials is most likely to be most practice changing?

Submit your answer to see the results

HARMONi-2
   
TROPION-Lung01
   
EVOKE-02
   
Other
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which is the most important for drug development in late-stage EGFR-wildtype NSCLC?

Submit your answer to see the results

Novel combinations, including dual immunotherapy options
   
Tumour infiltrating lymphocytes (TILs)
   
Cancer vaccines
   
Antibody–drug conjugates
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

What are you most interested in learning about from ongoing clinical trials?

Submit your answer to see the results

Outcomes in patients with brain metastases
   
Outcomes in high-risk patients
   
Role of biomarkers in personalizing treatment
   
Overall survival rates for combination approaches
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which of the following treatments is most likely to change your clinical practice?

Submit your answer to see the results

Osimertinib + chemotherapy
   
Amivantamab + lazertnib
   
Amivantamab + chemotherapy
   
Other
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which is the most important area for research in late-stage EGFR-mutant NSCLC?

Submit your answer to see the results

Management of CNS metastases/leptomeningeal disease
   
Biomarkers to monitor/predict treatment response
   
Identifying patients for risk-adaptive treatment strategies
   
Understanding specific resistance mutations
   
Play ArrowPlay Video

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which of the following topics do you feel will be most relevant to your practice?

Submit your answer to see the results

EGFR-mutations and targeted therapies
   
Emerging treatments and clinical trials for wildtype NSCLC
   
Patient support strategies and education
   
Biomarker testing for risk stratification
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

What emerging trends in biomarker testing are you most excited about?

Submit your answer to see the results

Development of novel biomarkers
   
Integration of liquid biopsies
   
Comprehensive genomic profiling
   
AI-enhanced analysis
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

What do you consider the biggest challenge for patients when navigating the NSCLC care pathway?

Submit your answer to see the results

Understanding treatment options
   
Managing side effects
   
Providing patient education and support
   
Communicating with healthcare providers
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

What are you most interested in learning about from ongoing clinical trials?

Submit your answer to see the results

Management of hard-to-treat patients
   
Options for second-line treatments (e.g. ADCs)
   
Outcomes in non-squamous vs squamous patients
   
Improved outcomes in the first-line setting
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which of the following trials is most likely to be most practice changing?

Submit your answer to see the results

HARMONi-2
   
TROPION-Lung01
   
EVOKE-02
   
Other
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which is the most important for drug development in late-stage EGFR-wildtype NSCLC?

Submit your answer to see the results

Novel combinations, including dual immunotherapy options
   
Tumour infiltrating lymphocytes (TILs)
   
Cancer vaccines
   
Antibody–drug conjugates
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

What are you most interested in learning about from ongoing clinical trials?

Submit your answer to see the results

Outcomes in patients with brain metastases
   
Outcomes in high-risk patients
   
Role of biomarkers in personalizing treatment
   
Overall survival rates for combination approaches
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which of the following treatments is most likely to change your clinical practice?

Submit your answer to see the results

Osimertinib + chemotherapy
   
Amivantamab + lazertnib
   
Amivantamab + chemotherapy
   
Other
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which is the most important area for research in late-stage EGFR-mutant NSCLC?

Submit your answer to see the results

Management of CNS metastases/leptomeningeal disease
   
Biomarkers to monitor/predict treatment response
   
Identifying patients for risk-adaptive treatment strategies
   
Understanding specific resistance mutations
   
Play ArrowPlay Video

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which of the following topics do you feel will be most relevant to your practice?

Submit your answer to see the results

EGFR-mutations and targeted therapies
   
Emerging treatments and clinical trials for wildtype NSCLC
   
Patient support strategies and education
   
Biomarker testing for risk stratification
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

What emerging trends in biomarker testing are you most excited about?

Submit your answer to see the results

Development of novel biomarkers
   
Integration of liquid biopsies
   
Comprehensive genomic profiling
   
AI-enhanced analysis
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

What do you consider the biggest challenge for patients when navigating the NSCLC care pathway?

Submit your answer to see the results

Understanding treatment options
   
Managing side effects
   
Providing patient education and support
   
Communicating with healthcare providers
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

What are you most interested in learning about from ongoing clinical trials?

Submit your answer to see the results

Management of hard-to-treat patients
   
Options for second-line treatments (e.g. ADCs)
   
Outcomes in non-squamous vs squamous patients
   
Improved outcomes in the first-line setting
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which of the following trials is most likely to be most practice changing?

Submit your answer to see the results

HARMONi-2
   
TROPION-Lung01
   
EVOKE-02
   
Other
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which is the most important for drug development in late-stage EGFR-wildtype NSCLC?

Submit your answer to see the results

Novel combinations, including dual immunotherapy options
   
Tumour infiltrating lymphocytes (TILs)
   
Cancer vaccines
   
Antibody–drug conjugates
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

What are you most interested in learning about from ongoing clinical trials?

Submit your answer to see the results

Outcomes in patients with brain metastases
   
Outcomes in high-risk patients
   
Role of biomarkers in personalizing treatment
   
Overall survival rates for combination approaches
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which of the following treatments is most likely to change your clinical practice?

Submit your answer to see the results

Osimertinib + chemotherapy
   
Amivantamab + lazertnib
   
Amivantamab + chemotherapy
   
Other
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Which is the most important area for research in late-stage EGFR-mutant NSCLC?

Submit your answer to see the results

Management of CNS metastases/leptomeningeal disease
   
Biomarkers to monitor/predict treatment response
   
Identifying patients for risk-adaptive treatment strategies
   
Understanding specific resistance mutations
   

touchCLINICAL PERSPECTIVES
A modular programme that includes a variety of interviews with experts and a patient, as well as downloadable resources. Close

Perspectives on EGFR-mutant and wildtype NSCLC: Tailoring treatment advances in late-stage disease

Claim Credit

Module 1 - Part 1: EGFR-mutant NSCLC: Navigating the horizon in EGFR-mutant NSCLC

Dr Helena Yu, course director and thoracic oncologist, discusses the unmet needs of patients with EGFR-mutant metastatic non-small cell lung cancer (NSCLC) by highlighting the current challenges, areas for further research and clinical trial landscape.

After watching this activity, participants should be better able to:

  1. Recall the latest clinical trial data for first- and second-line treatment options in patients with EGFR-mutant and wildtype NSCLC and their implications for treatment sequencing.

Module 1 - Part 2: EGFR-mutant NSCLC: Evaluating the latest advances in therapeutic strategies

Dr Antonio Passaro, an oncologist specializing in lung cancer, provides insights into the latest advances in therapeutic strategies for EGFR-mutant metastatic non-small cell lung cancer (NSCLC), focusing on recent clinical trial data in both the first- and second-line settings.

After watching this activity, participants should be better able to:

  1. Recall the latest clinical trial data for first- and second-line treatment options in patients with EGFR-mutant and wildtype NSCLC and their implications for treatment sequencing.

Module 1 - Part 3: EGFR-mutant NSCLC: Practical insights and implications for NSCLC practice

Dr Helena Yu provides an overview of the current treatment options for EGFR-mutant metastatic non-small cell lung cancer (NSCLC). She uses a patient case to explore both the existing therapies available at diagnosis and at the point of disease progression, as well as how ongoing research and the advent of new therapies and combination strategies might impact future treatment approaches.

After watching this activity, participants should be better able to:

  1. Recall the latest clinical trial data for first- and second-line treatment options in patients with EGFR-mutant and wildtype NSCLC and their implications for treatment sequencing.
  2. Use knowledge of efficacy and safety data for current and emerging first- and second-line treatments in patients with EGFR-mutant and wildtype NSCLC to develop optimal care pathways and improved clinical outcomes.

Module 2 – Part 1: Advances in the treatment landscape for EGFR-wildtype NSCLC

Dr Helena Yu, course director and thoracic oncologist, discusses the unmet needs of patients with EGFR-wildtype metastatic non-small cell lung cancer (NSCLC) by highlighting the current challenges, areas for further research and clinical trial landscape.

After watching this activity, participants should be better able to:

  1. Recall the latest clinical trial data for first- and second-line treatment options in patients with EGFR-mutant and wildtype NSCLC and their implications for treatment sequencing.

 

Module 2 – Part 2: EGFR-wildtype NSCLC: Insights from the latest data and strategies for improvement

Dr Aaron Lisberg, a thoracic oncologist specializing in patients with advanced malignancies, with a focus on lung cancer, provides insights into the latest advances in therapeutic strategies for EGFR-wildtype metastatic non-small cell lung cancer (NSCLC), focusing on recent clinical trial data in both the first- and second-line settings

After watching this activity, participants should be better able to:

  1. Recall the latest clinical trial data for first- and second-line treatment options in patients with EGFR-mutant and wildtype NSCLC and their implications for treatment sequencing.

Module 2 – Part 3: EGFR-wildtype NSCLC: Practical insights and implications for NSCLC practice

Dr Sara Pilotto, a medical oncologist specializing in thoracic malignancies, provides an overview of the current treatment options for EGFR-wildtype metastatic non-small cell lung cancer (NSCLC). She uses a patient case to explore both the existing therapies available at diagnosis and key considerations at disease progression, as well as how ongoing research and the advent of new therapies, such as antibody–drug conjugates, might impact future treatment approaches.

After watching this activity, participants should be better able to:

  1. Recall the latest clinical trial data for first- and second-line treatment options in patients with EGFR-mutant and wildtype NSCLC and their implications for treatment sequencing
  2. Use knowledge of efficacy and safety data for current and emerging first- and second-line treatments in patients with EGFR-mutant and wildtype NSCLC to develop optimal care pathways and improved clinical outcomes.

Module 3 - Part 1: Novel strategies, care pathways and side-effect management

Jackie Fenemore, a lung cancer nurse clinician, looks at how understanding the latest therapies can significantly impact patient care by effectively managing side effects and aligning treatment plans with patient expectations. She also highlights the essential supports that can be implemented to guide patients through the complexities of lung cancer care pathways.

After watching this activity, participants should be better able to:

  1. Use knowledge of efficacy and safety data for current and emerging first- and second-line treatments in patients with EGFR-mutant and wildtype NSCLC to develop optimal care pathways and improved clinical outcomes

Module 3 - Part 2: Implications of novel treatments on the shifting biomarker landscape

Prof. Dr Egbert Smit, a professor of pulmonary medicine, emphasizes the important role of biomarker testing in patients with EGFR-mutant and wildtype non-small cell lung cancer (NSCLC). He discusses how advances in the treatment landscape are influencing biomarker testing strategies and how this impacts patient care, as well as the challenges clinicians face, including sample acquisition, the need for timely testing, interpretation of results, and integration of findings into personalized treatment approaches.

After watching this activity, participants should be better able to:

  1. Describe the evolving landscape for biomarker testing in NSCLC and how this may impact current and future treatment decision making

Module 3 - Part 3: Optimizing outcomes in late-stage NSCLC: Key learnings

Dr Helena Yu, course director and thoracic oncologist, provides an overview of the three modules focusing on EGFR-mutant and wildtype non-small cell lung cancer (NSCLC). In this session, she summarizes the key learnings from each module while also providing timely updates on data presented at the World Conference on Lung Cancer (WCLC) and the European Society for Medical Oncology (ESMO) 2024 congresses. Dr Yu highlights how these recent findings can impact current NSCLC practices, addresses outstanding practice gaps, and outlines future directions in the rapidly evolving field of lung cancer management.

After watching this activity, participants should be better able to:

  1. Recall the latest clinical trial data for first- and second-line treatment options in patients with EGFR-mutant and wildtype NSCLC and their implications for treatment sequencing
  2. Describe the evolving landscape for biomarker testing in NSCLC and how this may impact current and future treatment decision making
  3. Use knowledge of efficacy and safety data for current and emerging first- and second-line treatments in patients with EGFR-mutant and wildtype NSCLC to develop optimal care pathways and improved clinical outcomes

Topics covered in this activity

Lung Cancer
REGISTER NOW FOR FREE ACCESS TO
  • 1000+ topical and insightful peer-reviewed journal articles
  • 1000+ topical and insightful peer-reviewed journal articles
  • 10 major therapy areas packed with the latest scientific advances
  • 150+ specialties offering learn-on-the-go medical education
  • + Concise email updates and newsletters so you never miss out
Register For Free Now
Claim Credit
touchCLINICAL PERSPECTIVES
Perspectives on EGFR-mutant and wildtype NSCLC: Tailoring treatment advances in late-stage disease
1.5 CE/CME credit

Question 1/6
Which of the following statements best reflects the recent outcomes of the FLAURA2 trial evaluating osimertinib ± Pt-ChT in EGFR-mutant NSCLC?

AE, adverse event; CNS, central nervous system; EGFR, epidermal growth factor receptor; PFS, progression-free survival; Pt-ChT, platinum-based chemotherapy.

The phase III FLAURA2 study, investigating osimertinib ± Pt-ChT in EGFR-mutant advanced NSCLC, demonstrated a median PFS of 25.5 months in the overall population receiving the combination vs 16.7 months in patients receiving osimertinib alone (HR 0.62; 95% CI 0.49–0.79; p<0.001). A PFS benefit in favour of the combination group was observed across prespecified subgroup populations, including patients with an exon 19 deletion, exon 21 (L858R) mutation, with CNS metastases and without CNS metastases. The rate of grade ≥3 AEs was higher in the combination group than the osimertinib monotherapy group (64 vs 27%).

Abbreviations
AE, adverse event; CI, confidence interval; CNS, central nervous system; EGFR, epidermal growth factor receptor; HR, hazard ratio; NSCLC, non-small cell lung cancer; PFS, progression-free survival; Pt-ChT, platinum-based chemotherapy.

Reference
Planchard D, et al. N Engl J Med. 2023;389:1935–48.

Question 2/6
Your patient is a 54-year-old woman with a stage IV EGFR-mutant NSCLC harbouring an exon 19 deletion mutation. Following administration of osimertinib QD for a period of 18 months, she has evidence of disease progression with the development of brain metastases. Which of the following agents might you select based on recent clinical trial data (and providing all agents are available) that could be added to the standard of care chemotherapy in the second-line setting to improve your patient’s outcomes?

EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; QD, once daily.

The phase III MARIPOSA-2 evaluated intravenous amivantamab + chemotherapy with or without lazertinib vs chemotherapy alone in patients with EGFR-mutant advanced NSCLC after disease progression on osimertinib. PFS was significantly longer with amivantamab + chemotherapy vs chemotherapy alone in all randomized patients (HR 0.48; 95% CI 0.36–0.64; p<0.001) and in patients with a history of brain metastasis (HR 0.52; 95% CI 0.35–0.78).1  

The PFS was also significantly longer in the amivantamab + lazertinib + chemotherapy arm vs chemotherapy alone (HR 0.44, 95% CI 0.35-0.56, p< 0.001). However, AEs of grade 3 or higher, mainly due to haematologic toxicities, were higher in the amivantamab + lazertinib + chemotherapy arm vs both amivantamab + chemotherapy and chemotherapy alone, which led to a regimen change during the trial for the triplet therapy arm.1 Longer follow-up is required for this modified regimen.

The antibody–drug conjugate patritumab deruxtecan has been evaluated as a third- or later-line monotherapy agent only in patients who had previously been treated with osimertinib and one or more prior lines of chemotherapy in the HERTHENA-Lung01 study.2 

Abbreviations

AE, adverse event; CI, confidence interval; EGFR, epidermal growth factor receptor; HR, hazard ratio; NSCLC, non-small cell lung cancer; PFS, progression-free survival. 

References

  1. Passaro A, et al. Ann Oncol. 2024;35:77–90.
  2. Yu HA, et al. J Clin Oncol. 2023;41:5363–75.
Question 3/6
What was a main finding from the phase III POSEIDON trial, assessing durvalumab + Pt-ChT ± tremelimumab in patients with metastatic EGFR/ALK-wildtype NSCLC?

ALK, anaplastic lymphoma kinase; CTLA-4, cytotoxic T-lymphocyte antigen 4; EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; OS, overall survival; PFS, progression-free survival; Pt-ChT, platinum-based chemotherapy.

The POSEIDON trial assessed durvalumab + Pt-ChT ± tremelimumab vs durvalumab + Pt-ChT vs Pt-ChT alone in patients with metastatic EGFR/ALK-wildtype NSCLC.1 In the non-squamous population, median OS at a median follow-up of 63.4 months was 17.2 months in the triplet therapy arm (n=214), 14.8 months in the doublet therapy arm (n=209) and 13.0 months in the Pt-ChT monotherapy arm (n=214), demonstrating a sustained OS benefit of triplet therapy over PT-ChT monotherapy (HR 0.76; 95% CI 0.64–0.89).1 Median OS in the squamous population was 10.4 months in the triplet therapy arm (n=124), 11.5 months in the doublet therapy arm (n=128) and 10.5 months in the Pt-ChT monotherapy arm (n=122).2 Over the extended follow-up, no new safety signals were identified.1,2

Abbreviations

ALK, anaplastic lymphoma kinase; CI, confidence interval; EGFR, epidermal growth factor receptor; HR, hazard ratio; NSCLC, non-small cell lung cancer; OS, overall survival; Pt-ChT, platinum-based chemotherapy.

References

  1. Peters S, et al. Ann Oncol. 2023;20(Suppl. 1):100535.
  2. Peters S, et al. Presented at: ESMO Immuno-Oncology 2023, Geneva, Switzerland. 6–8 December 2023. LBA3.
Question 4/6
Your 52-year-old female patient has stage IV, non-squamous NSCLC and a performance status of 1. Next-generation sequencing showed no first-line actionable genomic alterations but KRAS/STK11/KEAP1 co-mutations, and immunohistochemistry showed a PD-L1 tumour proportion score of <1%. Assuming all of the following options are available, which trial would you recommend for your patient?

ChT, chemotherapy; KEAP1, kelch like ECH associated protein 1; KRAS, Kirsten rat sarcoma viral oncogene homolog; NSCLC, non-small cell lung cancer; PD-L1, programmed death ligand-1; STK11, serine/threonine kinase 11.

For patients with advanced/metastatic non-squamous NSCLC with no actionable genomic alterations, no contraindications to immunotherapy and any expression of PD-L11 or PD-L1 tumour proportion score <1%,2 the combination of Pt-ChT + PD-1/PD-L1 blockade (e.g. pembrolizumab + platinum + pemetrexed) is recommended.1,2 However, a subgroup analysis of the POSEIDON trial showed that overall survival benefit was maintained with durvalumab + tremelimumab + Pt-ChT vs Pt-ChT alone in patients with KRAS-mutant, STK11mutant or KEAP1-mutant metastatic NSCLC.3 This led to initiation of TRITON, a phase III trial further comparing first-line durvalumab + tremelimumab + Pt-ChT vs pembrolizumab + Pt-ChT alone in patients with EGFR/ALK wildtype, non-squamous, metastatic NSCLC with KRAS, STK11 or KEAP1 mutations/co-mutations and a performance status of 0 or 1.4 The patient’s profile used here matches the eligibility criteria for TRITON, making enrolment in this trial a good option.

Abbreviations

ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; KEAP1, kelch like ECH associated protein 1; KRAS, Kirsten rat sarcoma viral oncogene homolog; NSCLC, non-small cell lung cancer; PD-L1, programmed death ligand-1; Pt-ChT, platinum-based chemotherapy; STK11, serine/threonine kinase 11. 

References

  1. Hendriks LE, et al. Ann Oncol. 2023;34:358–76.
  2. NCCN Clinical Practice Guidelines in Oncology. NSCLC Version 9.2024 — September 9, 2024. Available at: NCCN.org (accessed 11 September 2024).
  3. Peters S, et al. Presented at: ESMO Immuno-Oncology 2023, Geneva, Switzerland. 6–8 December 2023. LBA3.
  4. Skoulidis F, et al. J Clin Oncol. 2024;42(Suppl. 16):TPS8655.
Question 5/6
You are a specialist oncology nurse. A patient with extreme frailty has just received a diagnosis of metastatic NSCLC following an extended hospital stay due to malnourishment and cachexia. In addition to low BMI, the patient has spiking fevers and other active comorbidities. Assuming all options are available to you, what would you recommend for this patient during the multidisciplinary team meeting to ensure optimal care?

BMI, body mass index; NSCLC, non-small cell lung cancer.

A patient with a diagnosis of metastatic NSCLC in addition to extreme frailty and comorbidities may initially be advised to consider hospice care.1 However, a shared decision-making approach is encouraged, to engage with patients and caregivers,2 and to facilitate patient preferences and choices in line with their personal goals, with the aim of providing optimal care.1,2 With exceptional supportive care extending to include a dietitian, the patient’s immediate nutritional goals could be met, and the reasons behind the malnourishment could be identified and addressed through additional home-care services.1 If the patient’s performance status subsequently improved, appropriate treatment could then be considered.1

Abbreviation

NSCLC, non-small cell lung cancer.

References

  1. Ovesen L. Oncol Nurs News. 2023. Available at: www.oncnursingnews.com/view/oncology-nurses-are-uniquely-qualified-to-meet-the-needs-of-patients-with-lung-cancer (accessed 16 October 2024).
  2. Davies MD, Perkins S. TON. 2022. Available at: www.theoncologynurse.com/best-practices-education-for-patients-nsclc (accessed 16 October 2024).
Question 6/6
Your patient is receiving treatment with osimertinib for advanced, non-squamous, EGFR-mutant (exon 19 deletion) NSCLC. At a routine response assessment at around 13 months after treatment initiation, their CT scan shows evidence of systemic disease progression with multiple lesions. Their performance status is 1. What is your next step for this patient?

CT, computerized tomography; EGFR, epidermal growth factor receptor; NGS, next-generation sequencing; NSCLC, non-small cell lung cancer.

NCCN guidelines recommend a change in systemic therapy if a patient experiences symptomatic systemic progression and/or multiple lesions.1 While amivantamab plus carboplatin and pemetrexed is approved and the preferred second-line option for patients with non-squamous histology and multiple lesions,1–3 when considering second-line systemic therapy, patients should ideally be re-biopsied, when possible, to rule out histologic transformation and enable biomarker analysis.1,4 Genomic re-testing of a tumour that is actively progressing while exposed to targeted therapy can help guide the next therapeutic steps, e.g. alternate mechanisms of resistance (MET amplification, HER2 amplification),1,4 and may support clinical trial enrolment.4 A recent real-world study showed that patients with advanced EGFR-mutant NSCLC had better overall survival when their second-line therapy after progression on osimertinib was tailored based on biopsy results, compared with those who did not receive tailored second-line treatment (p=0.006).5 NCCN guidelines state that ctDNA testing should not be used in lieu of a histologic tissue diagnosis;1 ESMO guidelines recommend use of cell-free DNA when tissue samples are unavailable or in addition to tissue testing to reduce turnaround time.4

Abbreviations

ctDNA, circulating tumour DNA; EGFR, epidermal growth factor receptor; ESMO, European Society for Medical Oncology; HER2, human epidermal growth factor receptor 2; MET, mesenchymal-epithelial transition; NCCN, National Comprehensive Cancer Network®; NSCLC, non-small cell lung cancer.

References

  1. NCCN Clinical Practice Guidelines in Oncology. NSCLC Version 11.2024 — October 15, 2024. Available at: NCCN.org (accessed 16 October 2024).
  2. FDA. Amivantamab PI. Updated September 2024. Available at: https://bit.ly/4eLIKsA (accessed 16 October 2024).
  3. EMA. Amivanatamab SmPC. Updated September 2024. Available at: https://bit.ly/4hc1KCi (accessed 16 October 2024).
  4. Hendriks LE, et al. Ann Oncol. 2023;34:339–57.
  5. Choudhury NJ, et al. J Thorac Oncol. 2023;18:463–75.
Back to Activity